Lupus Research Alliance News
A “Call to Arms” for the Lupus Community

August 18, 2021 Many lupus patients are at risk for COVID-19 infection because of treatment with corticosteroids and other immunosuppressive medications and will be eligible for booster vaccination. However, there are large gaps in our understanding of who will benefit from the booster vaccines, what strategies will improve response to the vaccine and the best […] READ MORE

Two Studies Show COVID-19 Vaccines are Well-Tolerated Among Lupus Patients

August 12, 2021 In two recent studies, researchers found that the four COVID-19 vaccines are well-tolerated in lupus patients. Given that the Moderna and Pfizer vaccines are the first mRNA vaccines currently authorized for the emergency use in people, lupus researchers have since worked to answer questions specifically about potential side effects and whether these […] READ MORE

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] READ MORE

COVID-19 Took Significant Toll on People with Lupus

July 29, 2021 A new study showed that people with lupus experienced significant physical and emotional effects in the early months of the COVID-19 pandemic.   Including LRA Scientific Advisory Board member Jane Salmon, MD, researchers at Hospital for Special Surgery and Tufts University in Boston invited 97 patients to complete a questionnaire in the […] READ MORE

LRA’s Visionary Strategy to Turn Lupus Complexity to its Cure

July 15, 2021 Dear Friends, With much excitement, we introduce our new overarching approach to fulfilling LRA’s mission: Turning Complexity to Cure. Our goal is to involve the lupus community and beyond in our strategy to turn the core problem of lupus – its heterogeneity – how much it differs from person to person – into its solution through […] READ MORE

Learn and connect with our community!